KALA News and Press, Kala Pharmaceuticals Inc. From 06/23/23

ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards outside the Company’s Amended and Restated 2017 Equity ...

ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will prese...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designation for KPI-012 for the treatment of PCED -- -- S...

2023-04-28 10:06:26 ET Kala Pharma's ( NASDAQ: KALA ) subsidiary Combangio has been granted $15M by the California Institute for Regenerative Medicine (CIRM) to develop KPI-012 for the treatment of persistent corneal epithelial defect. ( KALA ) has risen 9.4% . The...

MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today anno...

2023-04-12 08:53:42 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Kala Pharmaceuticals' ( NASDAQ: KALA ) human mesenchymal stem cell secretome (MSC-S) therapy KPI-012 to treat persistent corneal epithelial defect (PCED), a rare and eye disorder. ...

ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the U.S. Foo...

2023-03-29 09:31:17 ET Kala Pharma ( NASDAQ: KALA ) said it had appointed Francis Mah as the company's Chief Medical Advisor. The company said Mah would serve in the role on a part time basis and will continue his ongoing position as Director of Cornea and Exter...

ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment o...